Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression

Nao Hiranuma(University of Washington), C. Anthony Blau(University of Washington), Wayne L. Monsky(University of Washington), Zhijun Duan(Dalian Medical University), Jacob A. Goldsmith(University of Washington), William Stafford Noble(University of Washington), Mary J. Goldman, Colin C. Pritchard(Animal and Plant Health Agency), Jill M. Johnsen(University of Washington), Francis M. Senecal(Northwest Medical Specialties), Sibel Blau(University of Washington Tacoma), Vijayakrishna K. Gadi(Fred Hutch Cancer Center), Elisabeth Mahen(University of Washington), Stephen C. Schmechel(Boise State University), Vitalina Komashko, Walter L. Ruzzo(University of Copenhagen), Patrick Soon‐Shiong(ImmunityBio (United States)), David Haussler(Santa Cruz County Office of Education), Marissa LaMadrid-Hermannsfeldt(University of Washington), Jie Liu(University of Michigan), Stephanie Parker(Northwest Medical Specialties), Kimberly A. Burton(University of Washington), Michael O. Dorschner(University of Washington), Stephen K. Allison(University of Washington), Sophie R. Salama(University of California, Santa Cruz), Shelly Heimfeld(Fred Hutch Cancer Center), Steven C. Benz, Jingchun Zhu(University of California, Santa Cruz), Chao-Zhong Song(University of Washington), Amie Radenbaugh(University of California, Santa Cruz)
bioRxiv (Cold Spring Harbor Laboratory)
November 5, 2016
Cited by 1


Related Papers